Trial Profile
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Spartalizumab (Primary) ; Antineoplastics
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 25 Aug 2021 Results published in the Clinical Cancer Research
- 20 Jul 2021 Status changed from active, no longer recruiting to completed.
- 12 Jan 2021 Planned End Date changed from 30 Oct 2020 to 17 Feb 2021.